evocatal invests in high-throughput technology and multiplies its screening capacity

03-Dec-2010 - Germany

The evocatal GmbH puts its new high-throughput screening lab located in the Life-Science Centre Duesseldorf into operation. The company multiplies its capacity for the development of new enzymes with this step. Accordingly the time-to-market period is significantly shortened through automization.

Together with the scientific advisory board and evocatal’s 17-strong team CSO Dr. Christian Leggewie opens up the newly established high-throughput laboratory in the Life Science Centre Duesseldorf.

The investment enables evocatal to reduce development periods for customized biocatalysts immensely. This applies for projects with cooperation partners as well as for supplying efficient enzymes for the internal production of fine chemicals.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances